Pidnarulex + Trastuzumab Deruxtecan for HER2-Positive Breast Cancer

This trial tests a new combination of treatments for individuals with certain types of breast cancer and other solid tumors that have spread or cannot be surgically removed. The trial combines two drugs: pidnarulex, which inhibits cancer cell growth, and trastuzumab deruxtecan, which targets and kills cancer cells with the HER2 protein. The goal is to determine the safest and most effective dose of these drugs when used together. This trial may suit someone whose breast cancer has spread or is advanced, especially if standard treatments are no longer viable. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new combination therapy.

The trial does not specify if you need to stop taking your current medications, but it does exclude participants taking strong CYP3A4 inhibitors or inducers, as these can affect the trial drugs. It's best to discuss your current medications with the trial team to see if they might interact with the study drugs.

Research has shown that pidnarulex has potential benefits in early studies, aiding patients with specific genetic mutations linked to breast and ovarian cancer. However, it remains in the early stages of testing to determine its safety and tolerability.

In contrast, trastuzumab deruxtecan is already in medical use. Studies confirm its general safety, though side effects can occur. Approximately 7% of patients discontinued its use due to these effects, and around 13% experienced lung problems known as interstitial lung disease (ILD).

Researchers are excited about Pidnarulex + Trastuzumab Deruxtecan for HER2-positive breast cancer because it introduces a new approach to tackling this aggressive form of cancer. While most treatments focus on blocking the HER2 receptor, Pidnarulex works by targeting and disrupting the DNA repair process in cancer cells, potentially leading to more effective cancer cell death. Trastuzumab Deruxtecan, on the other hand, is an antibody-drug conjugate that delivers chemotherapy directly to cancer cells, minimizing damage to healthy cells. This combination could enhance treatment effectiveness while reducing side effects compared to traditional chemotherapy.

Research has shown that trastuzumab deruxtecan yields promising results for treating HER2-positive breast cancer. In one study, 67.3% of patients experienced complete tumor disappearance. Another study found that 35.9% of patients saw tumor shrinkage. In this trial, participants will receive a combination of trastuzumab deruxtecan and pidnarulex.